Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis

Luo,Zhiqiang; Liu,Minglu; Sun,Likun; Rui,Feilong

doi:10.3892/mmr.2015.3369

Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis

Authors:
- Zhiqiang Luo
- Minglu Liu
- Likun Sun
- Feilong Rui
View Affiliations

Affiliations: The Second Clinical Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, School of Life Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, School of Physical Education, Tianshui Normal University, Tianshui, Gansu 741000, P.R. China
Published online on: February 17, 2015 https://doi.org/10.3892/mmr.2015.3369
Pages: 382-388

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of recent studies have suggested that icariin (ICA), a class of phytochemical with numerous biological activities, may exert protective effects against postmenopausal bone loss. However, it remains unclear whether ICA regulates or improves the osteoblastic function of bone marrow stromal cells (BMSCs) in the treatment and prevention of osteoporosis. In the present study, the osteogenic differentiation of BMSCs from ovariectomy (OVX) rats was found to be significantly decreased in vitro compared with that in rats that had undergone a sham operation. Treatment with ICA at a dose of 10‑5 M was shown to restore the osteogenic differentiation of BMSCs in OVX rats. The results indicated that ICA restored the differentiation and mineralization capacity of OVX‑BMSCs, which had been induced by estrogen deficiency. The effects of this compound on alkaline phosphatase (ALP) activity and calcium deposition were also measured at various time points. The number of colonies and areas that stained positive for ALP expression, and mineralized bone nodules were analyzed histochemically at 14 and 21 days after the osteogenic induction. The expression of the runt‑related transcription factor 2 and osterix bone metabolism biomarker proteins and genes were detected by western blotting and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The expression of factors involved in the estrogen signaling pathway, estrogen receptor α (ERα), progesterone receptor (PR) and trefoil factor 1 (PS‑2), was also detected by western blotting and RT‑qPCR. ICA enhanced the expression of ERα, PR, PS‑2 in OVX‑BMSCs, but this effect was abrogated when ICI 182780, an ER antagonist was added. Transplantation of BMSCs into nude mice demonstrated that ICA restored the osteogenic capability of OVX‑BMSCs in vivo. Therefore, it may be that ICA acts through the estrogen pathway in order to improve and restore the osteogenic differentiation and mineralization of OVX‑BMSCs, which are inhibited by estrogen deficiency and increasing age.

View Figures

View References

1	McGarry KA and Kiel DP: Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture. Postgrad Med. 108:79–82. 85–88. 912000. View Article : Google Scholar : PubMed/NCBI
2	Hertrampf T, Gruca MJ, Seibel J, et al: The bone-protective effect of the phytoestrogen genistein is mediated via ER alpha-dependent mechanisms and strongly enhanced by physical activity. Bone. 40:1529–1535. 2007. View Article : Google Scholar : PubMed/NCBI
3	Negishi-Koga T, Shinohara M, Komatsu N, et al: Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 17:1473–1481. 2011. View Article : Google Scholar : PubMed/NCBI
4	Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. 2008. View Article : Google Scholar
5	Liu Y, Wang L, Kikuiri T, et al: Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 17:1594–1601. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
7	Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am J Pathol. 170:427–435. 2007. View Article : Google Scholar : PubMed/NCBI
8	Riggs BL and Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 348:618–629. 2003. View Article : Google Scholar : PubMed/NCBI
9	Couse JF and Korach KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 20:358–417. 1999. View Article : Google Scholar : PubMed/NCBI
10	Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science. 295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
11	Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
12	Belandia B and Parker MG: Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell. 114:277–280. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ming LG, Chen KM and Xian CJ: Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodelling. J Cell Physiol. 228:513–521. 2013. View Article : Google Scholar
14	Chen KM, Ge BF, Ma HP, et al: Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie. 60:939–942. 2005.
15	Chen KM, Ma HP, Ge BF, et al: Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie. 62:388–391. 2007.PubMed/NCBI
16	Yamaza T, Miura Y, Bi Y, et al: Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One. 3:e26152008. View Article : Google Scholar : PubMed/NCBI
17	Hsieh TP, Sheu SY, Sun JS and Chen MH: Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. Phytomedicine. 18:176–185. 2011. View Article : Google Scholar
18	Huang J, Yuan L, Wang X, et al: Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci. 81:832–840. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhai YK, Ge BF and Ma HP: Comparative study on the osteogenic differentiation of rat bone marrow stromal cells effected by icariin and icariside II. Zhong Yao Cai. 33:1896–1900. 2010.In Chinese.
20	Zhai YK, Ge BF and Ma HP: Icariin promotes osteogenic differentiation of rat bone marrow stromal cells in vitro. Zhongguo Zhong Yao Za Zhi. 35:3219–3222. 2010.In Chinese.
21	Ma HP, Ming LG and Ge BF: Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem. 112:916–923. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ming LG, Zhou J, Cheng GZ, et al: Osthol, a coumarin isolated from common cnidium fruit, enhances the differentiation and maturation of osteoblasts in vitro. Pharmacology. 88:33–43. 2011. View Article : Google Scholar : PubMed/NCBI
23	Mok SK, Chen WF and Lai WP: Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol. 159:939–949. 2010. View Article : Google Scholar : PubMed/NCBI
24	Powell ME and Smith MJ: The determination of serum acid and alkaline phosphatase activity with 4-aminoantipyrine (A.A.P.). J Clin Pathol. 7:245–248. 1954. View Article : Google Scholar : PubMed/NCBI
25	Nian H, Ma MH, Nian SS and Xu LL: Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine. 16:320–326. 2009. View Article : Google Scholar : PubMed/NCBI
26	Zhang ZB and Yang QT: The testosterone mimetic properties of icariin. Asian J Androl. 8:601–605. 2006. View Article : Google Scholar : PubMed/NCBI
27	Ning H, Xin ZC, Lin G, et al: Effects of icariin on phosphodies-terase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology. 68:1350–1354. 2006. View Article : Google Scholar : PubMed/NCBI
28	Dell’Agli M, Galli GV, Dal Cero E, et al: Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 71:1513–1517. 2008. View Article : Google Scholar
29	Xu HB and Huang ZQ: Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol. 47:18–24. 2007. View Article : Google Scholar : PubMed/NCBI
30	Bian Q, Huang JH, Liu SF, et al: Different molecular targets of icariin on bMSCs in CORT and OVX-rats. Front Biosci (Elite Ed). 4:1224–1236. 2012. View Article : Google Scholar
31	Barkhem T, Haldosén LA, Gustafsson JA and Nilsson S: Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. Mol Endocrinol. 16:2571–2581. 2002. View Article : Google Scholar : PubMed/NCBI
32	Zampese E, Fasolato C, Pozzan T and Pizzo P: Presenilin-2 modulation of ER-mitochondria interactions: FAD mutations, mechanisms and pathological consequences. Commun Integr Biol. 4:357–360. 2011. View Article : Google Scholar : PubMed/NCBI
33	Hsieh TP, Sheu SY, Sun JS, et al: Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine. 17:414–423. 2011. View Article : Google Scholar